PTPN14 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16375396	1.00	1/20
SCHEMBL30366901	1.00	1/20
SCHEMBL16376118	0.92	1/20
SCHEMBL17669849	0.86	1/20
SCHEMBL16375397	0.83	1/20
SCHEMBL16376121	0.83	1/20
SCHEMBL18323176	0.79	1/20
SCHEMBL16375402	0.77	1/20
SCHEMBL30367054	0.77	1/20
SCHEMBL16376122	0.77	1/20
SCHEMBL18323109	0.77	1/20
SCHEMBL18323108	0.76	1/20
SCHEMBL16375399	0.75	1/20
SCHEMBL18323118	0.75	1/20
SCHEMBL30366941	0.75	1/20
SCHEMBL16376230	0.75	1/20
SCHEMBL16376231	0.73	1/20
SCHEMBL17669825	0.73	1/20
SCHEMBL16376232	0.72	1/20
SCHEMBL16375404	0.72	1/20

Clinical trials — most relevant to PTPN14 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance	PHASE2	COMPLETED
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer	PHASE2	UNKNOWN
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer	PHASE2	RECRUITING
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	PHASE1	RECRUITING
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
PCM1-JAK2 in Therapy Related Neoplasms	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
rT3 and Inflammation in Hashimoto's Thyroiditis	nan	COMPLETED
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PTPN14 binder may also engage these)

Protein	Name	Similarity
Q62136	—	1.000	Q62136 →
PTPN21	Protein-tyrosine phosphatase D1	1.000	landscape →
Q62130	—	1.000	Q62130 →
Q62728	—	1.000	Q62728 →
Q9Y2L6	—	0.995	Q9Y2L6 →
Q96NE9	—	0.992	Q96NE9 →
Q9HAU0	—	0.992	Q9HAU0 →
Q8C0V9	—	0.991	Q8C0V9 →
Q920B0	—	0.991	Q920B0 →
A5D794	—	0.990	A5D794 →
Q5M824	—	0.990	Q5M824 →
P34908	—	0.990	P34908 →
P59281	—	0.989	P59281 →
Q62415	—	0.989	Q62415 →
Q812E4	—	0.989	Q812E4 →
Q9H694	—	0.989	Q9H694 →
Q13905	—	0.989	Q13905 →
Q62925	—	0.989	Q62925 →
Q4V8Y7	—	0.989	Q4V8Y7 →
D4AB98	—	0.989	D4AB98 →
Q8TDW5	—	0.989	Q8TDW5 →
Q90738	—	0.989	Q90738 →
Q5U4T7	—	0.989	Q5U4T7 →
Q921C3	—	0.988	Q921C3 →
Q9ULM0	—	0.988	Q9ULM0 →
Q02225	—	0.987	Q02225 →
Q7Z2D5	—	0.987	Q7Z2D5 →
P49140	—	0.987	P49140 →
Q9P203	—	0.987	Q9P203 →
Q80YS6	—	0.987	Q80YS6 →